Publicacions en què col·labora amb Carlos Panizo Santos (17)

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  2. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

2019

  1. Análisis de las alteraciones de la coagulación y fibrinolisis

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 207-216

  2. Hemograma. Alteraciones eritrocitarias. Hemoglobinopatías

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 105-119

  3. Metabolismo del hierro. Anemia ferropénica. Hemocromatosis

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 121-130

  4. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  5. Síntesis y degradación dle hemo. Porfiria. Hiperbilirrubinemia

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 131-141

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

2010

  1. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

    Blood, Vol. 116, Núm. 14, pp. 2531-2542

2008

  1. Systemic lupus erythematosus and Franklin's disease: When the somatic mutation mechanism makes a mistake

    Rheumatology

2003

  1. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases

    Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181

2002

  1. A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome

    Genes Chromosomes and Cancer, Vol. 35, Núm. 1, pp. 11-19

1998

  1. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP53 mutations

    Medical and Pediatric Oncology, Vol. 30, Núm. 3, pp. 165-169

1997

  1. Estudio clínico y evolutivo de la leucemia de células plasmáticas. A propósito de nueve casos

    Revista Clinica Espanola, Vol. 197, Núm. 5, pp. 341-345